GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sopharma AD-Sofia (WAR:SPH) » Definitions » Gross Profit

Sopharma AD-Sofia (WAR:SPH) Gross Profit : zł911 Mil (TTM As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Sopharma AD-Sofia Gross Profit?

Sopharma AD-Sofia's gross profit for the three months ended in Jun. 2024 was zł226 Mil. Sopharma AD-Sofia's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was zł911 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Sopharma AD-Sofia's gross profit for the three months ended in Jun. 2024 was zł226 Mil. Sopharma AD-Sofia's Revenue for the three months ended in Jun. 2024 was zł1,070 Mil. Therefore, Sopharma AD-Sofia's Gross Margin % for the quarter that ended in Jun. 2024 was 21.08%.

Sopharma AD-Sofia had a gross margin of 21.08% for the quarter that ended in Jun. 2024 => Competition eroding margins

During the past 13 years, the highest Gross Margin % of Sopharma AD-Sofia was 26.40%. The lowest was 21.11%. And the median was 23.12%.

Warning Sign:

Sopharma AD-Sofia gross margin has been in long-term decline. The average rate of decline per year is -1.4%.


Sopharma AD-Sofia Gross Profit Historical Data

The historical data trend for Sopharma AD-Sofia's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sopharma AD-Sofia Gross Profit Chart

Sopharma AD-Sofia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 660.91 664.22 746.50 779.52 887.93

Sopharma AD-Sofia Quarterly Data
Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 223.01 192.31 247.34 245.61 225.56

Competitive Comparison of Sopharma AD-Sofia's Gross Profit

For the Medical Distribution subindustry, Sopharma AD-Sofia's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma AD-Sofia's Gross Profit Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Gross Profit distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's Gross Profit falls into.


;
;

Sopharma AD-Sofia Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Sopharma AD-Sofia's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=4101.003 - 3213.071
=888

Sopharma AD-Sofia's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=1070.193 - 844.633
=226

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł911 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Sopharma AD-Sofia's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=226 / 1070.193
=21.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Sopharma AD-Sofia  (WAR:SPH) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sopharma AD-Sofia had a gross margin of 21.08% for the quarter that ended in Jun. 2024 => Competition eroding margins


Sopharma AD-Sofia Gross Profit Related Terms

Thank you for viewing the detailed overview of Sopharma AD-Sofia's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Sopharma AD-Sofia Business Description

Traded in Other Exchanges
Address
5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 11, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products; and Others. It generates the majority of its revenue from the Distribution of pharmaceutical products.